Robert Kelleher, MD
Internal Medicine · Watertown, MANPI 1891761714
Payments from drug & device makers
Across 404 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$820
- Novo Nordisk$712
- Amgen$595
- Lilly USA, LLC$577
- Pfizer$507
- plus $4K from 25 others
What the payments were for
- Food & beverage$8,362100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 80 | $1,579 |
| Johnson & Johnson | 27 | $820 |
| Novo Nordisk | 36 | $712 |
| Amgen | 23 | $595 |
| Lilly USA, LLC | 33 | $577 |
| Pfizer | 31 | $507 |
| Boehringer Ingelheim | 23 | $506 |
| GSK | 19 | $470 |
| AbbVie | 22 | $438 |
| Novartis | 21 | $339 |
| Merck | 21 | $325 |
| Amarin Pharma, Inc. | 7 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $175 |
| E.r. Squibb & Sons, L.L.C. | 9 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $139 |
| Astellas Pharma US Inc | 5 | $137 |
| Tolmar, Inc. | 7 | $115 |
| Idorsia Pharmaceuticals US Inc | 5 | $111 |
| Endo Pharmaceuticals Inc. | 4 | $76 |
| Almatica Pharma LLC | 2 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Abbott | 2 | $44 |
| Exact Sciences | 2 | $44 |
| Acerus Pharmaceuticals Corporation | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Halozyme Inc | 1 | $33 |
| Antares Pharma, Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$345
- Vascepa$122
- SHINGRIX$121
- TRINTELLIX$108
How this compares
$8,388 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $127,450 |
| OzempicSemaglutide | 39 | $42,987 |
| JardianceEmpagliflozin | 17 | $22,678 |
| XareltoRivaroxaban | 24 | $17,876 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,434 |
| JanuviaSitagliptin Phosphate | 12 | $10,743 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $9,690 |
| Atorvastatin Calcium | 512 | $8,027 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,327 |
| Valsartan | 116 | $4,663 |
| Lidocaine | 19 | $3,917 |
| Metoprolol Succinate | 142 | $3,506 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $3,006 |
| Lisinopril | 336 | $2,996 |
| Varenicline Tartrate | 11 | $2,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $507 | $127,450133 claims |
| Novo NordiskOzempic | $712 | $42,98739 claims |
| Boehringer IngelheimJardiance | $506 | $22,67817 claims |
| Johnson & JohnsonXarelto | $820 | $17,87624 claims |
| GSKTrelegy Ellipta | $470 | $16,43418 claims |
| MerckJanuvia | $325 | $10,74312 claims |
| AstraZenecaLokelma | $1,579 | $9,69012 claims |
| AbbVieSynthroid | $438 | $1,28416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Watertown
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.